Advertisement


Jack Cuzick, PhD, on the International Breast Cancer Intervention Study II: 10-Year Results

2019 San Antonio Breast Cancer Symposium

Advertisement

Jack Cuzick, PhD, of Queen Mary University of London, discusses the substantially greater benefits of anastrozole as compared with tamoxifen in terms of preventing breast cancer, with no increase in fractures or other reported serious side effects (Abstract GS4-04).



Related Videos

Breast Cancer

Miguel Martín, MD, PhD, on Metastatic Breast Cancer: PEARL Trial on Palbociclib Plus Endocrine Therapy vs Capecitabine

Miguel Martín, MD, PhD, of the Gregorio Marañón Institute and GEICAM, discusses phase III study findings that showed no improvement in progression-free survival with palbocic...

Breast Cancer

Hope S. Rugo, MD, on Metastatic Triple-Negative Breast Cancer: Retrospective Analysis of PD-L1 Immunohistochemistry Assays

Hope S. Rugo, MD, of the University of California San Francisco Comprehensive Cancer Center, discusses a retrospective analysis on the effectiveness of the VENTANA PD-L1 SP14...

Breast Cancer
Genomics/Genetics

Nicholas C. Turner, MD, PhD, on ctDNA Testing to Direct Targeted Therapies in Advanced Breast Cancer

Nicholas C. Turner, MD, PhD, of The Royal Marsden NHS Foundation Trust, discusses findings from the plasmaMATCH trial, which showed that circulating tumor DNA testing offers ...

Breast Cancer

Milan Radovich, PhD, on ctDNA After Neoadjuvant Chemotherapy and Recurrence in Triple-Negative Breast Cancer

Milan Radovich, PhD, of Indiana University School of Medicine, discusses trial findings that show patients with triple-negative breast cancer who are at high risk of relapse ...

Breast Cancer
Immunotherapy

Luca Gianni, MD, on the Neoadjuvant Treatment of Triple-Negative Breast Cancer

Luca Gianni, MD, of the Fondazione Michelangelo, discusses findings from the NeoTRIP trial on pathologic complete response to neoadjuvant treatment with or without atezolizum...

Advertisement

Advertisement



Advertisement